[A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]

A 69-year-old patient with advanced stomach cancer (Borrmann III) was treated with a combination chemotherapy regimen of cis-platinum administered one week after a course of PSK and FT-207. The maximum dosage of CDDP administered was gradually increased step by step from 20 mg/day to 40 mg/day every week. A remarkable decrease of tumor size was observed upon stomach x-ray and endoscopical examination. The cancer marker, serum CEA, determined by RIA also decreased from 59 ng/ml to 3.5 ng/ml. Moreover, no gastrointestinal disturbance was observed during this trial. From the results experienced, in this case, the combination therapy of PSK and FT-207 with CDDP was considered to be one of the most effective antineoplastic therapies available for stomach cancer, suppressing the gastrointestinal disturbances which are usually induced by CDDP administration alone.